TARIS Biomedical Initiates Clinical Study in Interstitial Cystitis Patients
3/9/2011 10:33:00 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS’ innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC. LiRIS® is designed to continuously deliver lidocaine over an extended period directly to the bladder to decrease symptoms associated with IC, such as bladder pain and voiding dysfunction.